ESR1 and breast carcinoma: Studies have shown that in hormone receptor–positive (HR+) breast cancer, PIK3CA mutations activate the PI3K pathway, promoting ligand-independent estrogen receptor (ER) activation, thereby leading to endocrine therapy resistance and accelerating disease progression (23, 24).